|
AI for pharmaceutical legislation, including nitrosamines
|
|
4
|
374
|
December 30, 2024
|
|
WHO good manufacturing practices considerations for the prevention and control of nitrosamine contamination in pharmaceutical products
|
|
4
|
1158
|
December 21, 2024
|
|
🇲🇽 Mexico Nitrosamine Guide published today
|
|
42
|
2949
|
November 22, 2024
|
|
Methylene Blue NDSRI
|
|
6
|
564
|
November 22, 2024
|
|
New EMA Nitrosamine impurities page
|
|
0
|
450
|
November 21, 2024
|
|
Terbinafine Nitrosamines
|
|
3
|
253
|
November 14, 2024
|
|
NDSRI limit for N-nitroso Ciprofloxacin
|
|
2
|
319
|
November 1, 2024
|
|
FDA Statement on Ritonavir and NITMA
|
|
1
|
359
|
October 29, 2024
|
|
Hexamethyldisilazane (HMDS) can form Nitrosamine Impurity?
|
|
7
|
563
|
October 29, 2024
|
|
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da -Pub
|
|
0
|
302
|
October 28, 2024
|
|
Nitroso Betahistine Impurity C
|
|
2
|
154
|
October 28, 2024
|
|
Use of L-cysteine as nitrite scavenging
|
|
6
|
329
|
October 25, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced AMES Test -Pub
|
|
0
|
124
|
October 14, 2024
|
|
Oral Liquid Formulations
|
|
4
|
221
|
October 14, 2024
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
5
|
1793
|
October 9, 2024
|
|
Dietary exposure assessment for volatile N-nitrosamines from food and beverages for the U.S. population -Pub
|
|
0
|
124
|
September 18, 2024
|
|
NDMA testing in metformin
|
|
5
|
252
|
September 9, 2024
|
|
Vildaglibtin and Metformin in combinationy
|
|
1
|
558
|
October 17, 2023
|
|
USP - CPCA Nitrosamines Case Study
|
|
7
|
1543
|
August 30, 2024
|
|
Resources to help educate reluctant excipient suppliers?
|
|
7
|
347
|
August 28, 2024
|
|
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting
|
|
1
|
110
|
August 27, 2024
|
|
Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices -Pub
|
|
0
|
403
|
August 27, 2024
|
|
🇧🇷 Guideline for the control of Nitrosamines Rev. 4
|
|
24
|
1929
|
August 21, 2024
|
|
AI for NDSRI by Brazil regulatory
|
|
6
|
923
|
August 7, 2024
|
|
South African Health Products Regulatory Authority (Nitrosamines)
|
|
2
|
729
|
August 5, 2024
|
|
👨💻 Dashboard Containing Published AI Limits
|
|
32
|
3787
|
August 2, 2024
|
|
🇲🇽 Coming July Mexico Nitrosamines Guideline
|
|
5
|
487
|
August 2, 2024
|
|
Extension of the implementation deadline for "Self-inspection on Risks of Contamination with Nitrosamines in Drug" in Japan
|
|
2
|
241
|
July 30, 2024
|
|
The clinical and regulatory status of NDSRI: A global imperative -Pub
|
|
1
|
283
|
July 30, 2024
|
|
EMA/CHMP Concept paper on the revision of the guideline on the chemistry of active substances
|
|
4
|
605
|
July 29, 2024
|